(0.01%) 5 479.00 points
(-0.01%) 38 815 points
(0.04%) 19 929 points
(0.30%) $80.57
(0.61%) $2.81
(0.15%) $2 332.60
(-0.22%) $29.33
(-0.01%) $970.80
(0.04%) $0.932
(-0.13%) $10.64
(0.07%) $0.788
(-1.87%) $86.80
@ $53.16
Išleistas: 17 birž. 2024 @ 21:31
Grąža: -0.85%
Ankstesnis signalas: birž. 17 - 20:55
Ankstesnis signalas:
Grąža: -0.83 %
Live Chart Being Loaded With Signals
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases...
Stats | |
---|---|
Šios dienos apimtis | 4 573 |
Vidutinė apimtis | 1.90M |
Rinkos kapitalizacija | 6.04B |
EPS | $-1.330 ( Q1 | 2024-05-10 ) |
Kita pelno data | ( $-1.070 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-9.76 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.550 (2.94%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-17 | Parshall B Lynne | Buy | 5 000 | Common Stock |
2024-06-17 | Parshall B Lynne | Sell | 5 000 | Common Stock |
2024-06-17 | Parshall B Lynne | Sell | 5 000 | Non-Qualified Stock Option (Right to Buy) |
2024-06-17 | Blum Robert I | Sell | 11 551 | Common Stock |
2024-06-17 | Blum Robert I | Sell | 10 949 | Common Stock |
INSIDER POWER |
---|
5.56 |
Last 99 transactions |
Buy: 573 733 | Sell: 523 480 |
Tūris Koreliacija
Cytokinetics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
KLXE | 0.905 |
AGRI | 0.903 |
BNAI | 0.901 |
BRLT | 0.9 |
FWRD | 0.897 |
SVC | 0.893 |
PZZA | 0.892 |
BCTX | 0.89 |
CHUY | 0.888 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
RFAIU | -0.918 |
GOGL | -0.9 |
GODN | -0.893 |
IBKR | -0.892 |
AFAR | -0.89 |
ACGL | -0.886 |
WING | -0.884 |
BYNO | -0.882 |
SFM | -0.877 |
APXI | -0.877 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cytokinetics Inc Koreliacija - Valiuta/Žaliavos
Cytokinetics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $7.53M |
Bruto pelnas: | $-4.36M (-57.93 %) |
EPS: | $-5.45 |
FY | 2023 |
Pajamos: | $7.53M |
Bruto pelnas: | $-4.36M (-57.93 %) |
EPS: | $-5.45 |
FY | 2022 |
Pajamos: | $94.59M |
Bruto pelnas: | $-146.23M (-154.59 %) |
EPS: | $-4.48 |
FY | 2021 |
Pajamos: | $70.43M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.68 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.